Defining Unmet Need Following Lenalidomide Refractoriness: Real-World Evidence of Outcomes in Patients With Multiple Myeloma

BACKGROUND: The treatment paradigm for multiple myeloma (MM) continues to evolve with the development of novel therapies and the earlier adoption of continuous treatments into the treatment pathway. Lenalidomide-refractory patients now represent a challenge with inferior progression free survival (P...

Descripción completa

Detalles Bibliográficos
Autores principales: Lecat, Catherine S. Y., Taube, Jessica B., Wilson, William, Carmichael, Jonathan, Parrish, Christopher, Wallis, Gabriel, Kyriakou, Charalampia, Lee, Lydia, Mahmood, Shameem, Papanikolaou, Xenofon, Rabin, Neil K., Sive, Jonathan, Wechalekar, Ashutosh D., Yong, Kwee, Cook, Gordon, Popat, Rakesh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8335564/
https://www.ncbi.nlm.nih.gov/pubmed/34367987
http://dx.doi.org/10.3389/fonc.2021.703233

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8335564/
https://www.ncbi.nlm.nih.gov/pubmed/34367987
http://dx.doi.org/10.3389/fonc.2021.703233

Ejemplares similares